#16,817
The search for safe and effective treatment options for COVID cases continues nearly 30 months into the pandemic - and while some have been identified - many therapeutic options that were viewed favorably 6 months or a year ago are no longer effective against the newer Omicron variants, or have failed to show clinical benefit.
Just as the virus changes over time, so must our approach to treating it.
Some recent blogs include:
FDA Limits Use Of Sotrovimab Monoclonal Antibody As Rising BA.2 Erodes Effectiveness
CDC EID Journal: High-Dose Convalescent Plasma for Treatment of Severe COVID-19
FDA Removes Authorization For Two Monoclonal Antibody Therapies Due To Omicron
CDC HAN #00461: Using Therapeutics to Prevent and Treat COVID-19
In another example, the NIH's most recent update to their Coronavirus Disease 2019 (COVID-19) Treatment Guidelines - after reviewing the results from several recent clinical trials - has issued new guidance for the use of Antithrombotic Therapy in Patients With COVID-19.
- The Panel recommends against the use of antiplatelet therapy to prevent COVID-19 progression or death in noncritically ill patients (BIIa).
- There is insufficient evidence for the Panel to recommend either for or against antiplatelet therapy in critically ill patients with COVID-19.
- The Panel recommends against routinely continuing venous thromboembolism (VTE) prophylaxis for patients with COVID-19 after hospital discharge, except in a clinical trial (AIII).
- For patients who are at high risk for VTE and low risk for bleeding, there is insufficient evidence to recommend either for or against continuing anticoagulation after hospital discharge unless another indication for VTE prophylaxis exists.
It is a lot for clinicians to keep up with, which is why the CDC has put together a COCA call for later this week (June 16th) summarizing the latest guidance on the treatment of COVID cases.
These presentations are often technical, and are of greatest interest to clinicians and healthcare providers, but also may be of interest to the general public.
I suspect this will be a heavily attended event. If you are unable to attend the live presentation, these (and past) webinars are always archived and available for later viewing at this LINK.
What Clinicians Need to Know About Available Therapeutic Options for COVID-19
Overview
Medications are available that can reduce chances of severe illness and death from COVID-19 infection. Oral antivirals are available that can reduce chances of severe illness and death from COVID-19 infection. The Food & Drug Administration issued emergency use authorizations for certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get sick. The National Institutes of Health also provides COVID-19 treatment guidelines for healthcare providers for treating COVID-19 at home or in an outpatient setting. During this COCA Call, subject matter experts will present an overview of COVID-19 therapeutic options, including indications, efficacy, and distribution.
Presenters
Dan Filardo, MD
Epidemic Intelligence Service Officer
Core Clinical Unit
Epidemiology Task Force
COVID-19 Response
Centers for Disease Control and Prevention
Eric Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Clinical Guidelines Team
National Institutes of Health
Call Details
When:
Thursday, June 16, 2022,
2:00 PM – 3:00 PM ET
Webinar Link:
https://www.zoomgov.com/j/1603960029
Passcode: 308026
Dial In:
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590
International numbers
One-tap mobile:
US: +16692545252,,1603960029#,,,,*308026# or +16468287666,,1603960029#,,,,*308026#
Webinar ID: 160 396 0029
